Exscientia signs Proof-of-Concept deal with Sunovion Inc. to discover ‘bi-specific’ compounds for psychiatric disease

Exscientia is pleased to announce the formation of a neuroscience  collaboration with Sunovion Inc.. The agreement focuses on ex scientia’s delivery of novel 'bispecific' compounds  that combine activities at the GPCR and ion channel super families to treat psychiatric diseases. In terms of the agreement ex scientia receives full research funding. Further financial terms were not disclosed.